Perspective Therapeutics Announces First Patient Treated With PSV359 In Phase 1/2A Dose-Finding Trial Assessing Safety And Preliminary Anti-Tumor Activity
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $17
Optimistic Buy Rating for Perspective Therapeutics Amid Strategic Clinical Developments and Strong Financial Position
Sector Update: Health Care Stocks Mixed Premarket Friday
12 Health Care Stocks Moving In Friday's Pre-Market Session
Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy
Express News | Perspective Therapeutics Announces First Patient Dosed With [212PB]Vmt01 Monotherapy at 1.5 Mci in a Phase 1/2a Study of Mc1R-Positive Metastatic Melanoma
Perspective Therapeutics Announces First Patient Dosed With [212Pb]VMT01 Monotherapy at 1.5 MCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $10
Truist Financial Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
Perspective Therapeutics Is Maintained at Buy by Truist Securities
Express News | Perspective Therapeutics Inc : Truist Securities Cuts Target Price to $10 From $21
Perspective Therapeutics Executives Make Major Stock Purchases!
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
Perspective Therapeutics | 10-K/A: Annual report (Amendment)
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $11 to $17